Global Shingles Vaccine Market: By Type (Live Attenuated Vaccines, Recombinant Subunit Vaccines, Total), By Application (Adult Vaccination, High-Risk Individuals, Total), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), And Segment Forecasts, 2020 – 2034, (USD Million).

The Global Shingles Vaccine Market study considers the base year 2024, the historic year 2020 to 2023, and the forecast year 2025 to 2034. According to the Global Data Route Analysis estimates, the global shingles vaccine market will increase from USD 33.22 billion in 2020 to USD 47.87 billion in 2024. It is projected that by 2034, the global market would have expanded to USD 141.46 billion at a Compound Annual Growth Rate (CAGR)% of 11.56 between the years 2025 and 2034.

Source: Primary research, secondary research and GDRA
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America is anticipated to lead the market, whereas Asia Pacific is projected to register the highest CAGR during the forecast period.

Source: Primary research, secondary research and GDRA

North America: The market revenue in North America increased from USD 19,921.34 million in 2020 to USD 28,828.21 million in 2024 and is projected to reach USD 85,949.19 million by 2034, growing at a CAGR of 11.66% during the forecast period (2025–2034). Europe: The European market generated USD 6,251.12 million in 2020, increasing to USD 8,945.70 million in 2024 and is expected to grow to USD 25,962.68 million by 2034, with a CAGR of 11.36% during the forecast period. Asia Pacific:

Source: Primary research, secondary research and GDRA

The market in Asia Pacific stood at USD 4,134.60 million in 2020, reached USD 6,043.50 million in 2024, and is forecasted to grow to USD 18,493.64 million by 2034, registering a CAGR of 11.95% between 2025 and 2034. Latin America: Latin America’s market size rose from USD 1,810.31 million in 2020 to USD 2,513.67 million in 2024 and is anticipated to reach USD 6,765.35 million by 2034, exhibiting a CAGR of 10.53% during the forecast period. Middle East & Africa: The Middle East & Africa market increased from USD 1,095.37 million in 2020 to USD 1,541.93 million in 2024 and is projected to reach USD 4,294.64 million by 2034, growing at a CAGR of 10.91% during the forecast period.
 
On the basis of type, the market is segmented into Live Attenuated Vaccines and Recombinant Subunit Vaccines: The Live Attenuated Vaccines: market revenue was USD 11,894.43 million in 2020, growing to USD 18,128.26 million in 2024, and is expected to reach USD 60,434.89 million by 2034, with a CAGR of 12.90% during the forecast period (2025–2034). Recombinant Subunit Vaccines: market revenue increased from USD 21,318.31 million in 2020 to USD 29,744.76 million in 2024 and is projected to reach USD 81,030.60 million by 2034, growing at a CAGR of 10.66% during the forecast period.

Source: Primary research, secondary research and GDRA

Based on application, the market is segmented into Adult Vaccination and High-Risk Individuals: Adult Vaccination: market size stood at USD 22,582.43 million in 2020, reached USD 32,866.67 million in 2024, and is anticipated to grow to USD 99,374.18 million by 2034, registering a CAGR of 11.82% between 2025 and 2034.

Source: Primary research, secondary research and GDRA

High-Risk Individuals: The revenue was USD 10,630.30 million in 2020, increasing to USD 15,006.35 million in 2024, and is expected to grow to USD 42,091.31 million by 2034, with a CAGR of 10.98% during the forecast period.
 
The reports include DROC, which stands for driver restraint opportunities in this market. They feature a SWOT analysis, which examines strengths, weaknesses, opportunities, and threats, and a PESTLE analysis, which looks at political, economic, social, technological, environmental, and legal factors. Additionally, the reports provide an evaluation using Porter’s Five Forces, the BCG matrix, soft metrics, and an overview of the competitive landscape.

Source: Primary research, secondary research and GDRA
 
Global Shingles Vaccine Market Segmentation

By Type
• Live Attenuated Vaccines
• Recombinant Subunit Vaccines

By Application
• Adult Vaccination
• High-Risk Individuals
________________________________________
Key Players in the Global Shingles Vaccine Market
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• CSL Limited
• Johnson & Johnson
• Novavax, Inc.
• Moderna, Inc.
• Bharat Biotech International Limited
• Sinovac Biotech Ltd.
• AstraZeneca plc
• Serum Institute of India Pvt. Ltd.
• Medicago Inc.
• BioNTech SE

Let me know if further adjustments are required!
“For a free sample report in PDF, Excel, or PPT format, contact us at sales@globaldatarouteanalytics.com.”

For a free TOC and sample report, please email us at sales@globaldatarouteanalytics.com.

For a free TOC and sample report, please email us at sales@globaldatarouteanalytics.com.

For a free TOC and sample report, please email us at sales@globaldatarouteanalytics.com.